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Abstract
Metronidazole may be of use in the treatment of infectious
mononucleosis (IM). Our aim is to show that metronidazole
shortens hospital stay for patients with severe IM. A single-centre
randomized controlled trial was undertaken in patients admitted
with severe IM, who were with a similar group treated by the
standard care. Patients were blinded to which treatment arm they
were in. Forty-two of these patients were enrolled in the trial. The
primary endpoint was the difference in length of stay. This was
significantly less in the metronidazole group (3.67 days v 4.67) (p
0.032). This study demonstrates that metronidazole has a role to
play in severe infectious mononucleosis.
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Metronidazole may be efficacious in the treatment of infectious
mononucleosis (IM) [1]. A possible mechanism of its action in
IM is through suppression of anaerobic flora [2–4]. Previous
studies have demonstrated a rapid regression of symptoms in
those taking metronidazole [1,5–8]; however, a single study
showed no difference [9]. The hypothesis of our study is that
metronidazole does shorten hospital stay.
The trial was a single-centre prospective randomized
controlled trial. Patients were randomized to one of two
arms, control or intervention, on a one-to-one basis. Patients
diagnosed with IM were eligible if they were 15 or over and
admitted to University Hospital Limerick (UHL), a tertiary
referral centre. Three other hospitals in the region referred all
cases for admission to UHL. Patients were recruited between
5 January 2010 and 11 April 2012. Patients were deemed
appropriate for admission, and therefore severe [10], if they
could not tolerate oral hydration or oral analgesia. Patients
were excluded if they were allergic to penicillin, were
pregnant, had an airway emergency, or were diagnosed with
CMV mononucleosis or other mononucleosis-like infections.
Steroids, if given in the Emergency Department (ED), were not
continued once the patients were admitted.
The standard dose of metronidazole (500 mg TDS intrave-
nously) was given at regular intervals at the same time as
benzylpenicillin (1.2 g TDS). Benzylpenicillin is given to patients
with IM to prevent a bacterial superinfection and complications
such as Lemierre’s syndrome [11,12]. It is part of the standard
care, including supportive treatment with intravenous hydra-
tion, antipyretics and analgesics, which all patients received.
No placebo was given.
The primary outcome measured was the difference in
length of stay (LOS) in days. Patients were discharged when
the consultant in charge of their care felt that they had made a
sufficient recovery and were unlikely to represent to the
hospital. Secondary outcomes included inflammatory markers,
(white cell count, WCC) and high temperature (over 38°C).
Randomization was carried out by simple randomization,
and allocation was concealed from the patient. The first author
carried out enrollment, randomization and allocation conceal-
ment. Patients were blinded to which treatment arm they
were in. Both groups received multiple injections and nurses
were asked not to inform patients of which arm they were in.
Statistical analysis was undertaken using SPSS. Subgroup
analysis was carried out on those who received steroids.
CONSORT guidelines were followed [13].
Ethical permission was sought and granted by the
Mid-Western Regional Ethics Research Committee (equivalent
to IRB approval) and all patients signed an informed consent
prior to being enrolled in the trial.
Fifty-one patients were admitted under the ENT service
with infectious mononucleosis. Forty-two of these patients
were enrolled in the trial. Eight patients were excluded: five
were allergic to penicillin, two were under the age of 15, and
one patient had an airway emergency. A single patient refused
to partake in the trial. Patients were followed as in-patients
and therefore there was no loss to follow-up. Three patients
who were initially in the control group were started on
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metronidazole but failed to show any sign of improvement.
These patients were analysed in their original group (Fig. 1).
The trial was stopped when sufficient numbers were recruited
to allow statistical analysis.
No significant difference in these baseline values, such as
age, sex, symptomatic days prior to admission, primary care
visits and antibiotic treatment prior to ED attendance, was
found between the two groups.
The primary endpoint in the study was the difference in
LOS. This was significantly less in the metronidazole group,
with a mean of 3.67 compared to 4.67 in the standard care
group (p 0.032). Differences in secondary endpoints were not
significant (Table 1). No adverse effects from metronidazole
were reported.
IM was once thought to be reminiscent of an anaerobic
infection [1]. A number of studies were therefore under-
taken to examine the possible role of metronidazole in the
treatment of IM. The majority of these studies support the
contention that metronidazole does indeed have a beneficial
action in those with severe IM [1,6–8], with a single paper
showing no significant effect [9]. The results of our study
here concur with the majority of those previously under-
taken that metronidazole shortens the duration of severe
IM.
The limitations of this study include its small size. The trial is
similar in size to the larger of the previously published studies
on the same subject [7,9]. Due to their small size and the fact
that the methods differ between them substantially, meta-analy-
sis of these studies may be misleading [14]. The lack of
publications with ‘negative’ results may be due to publication
bias towards those with ‘positive’ results. From a recently
published study on the epidemiology of the same population
[15], a mean of 18.5 patients a year were admitted, therefore
recruitment of 42 patients in 28 months was satisfactory.
Further weaknesses included the lack of a placebo. The trial
was carried out within a clinical setting with no added funding.
The primary author carried out most of the recruitment,
allocation, randomization and data gathering, as well as the
statistical analysis, thus leading to the risk of multiple biases,
including reporting bias and multiplicity. Randomization was
FIG. 1. Patient flow diagram.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O450–O452
CMI Research Note O451
also carried out by simple randomization, but baseline values in
both groups are similar.
The results of this trial can be applied to a small but
noteworthy cohort of patients: those with severe IM that
require admission to hospital.
A greater number of anaerobes have been found on tonsils
during an infection with IM than when the patient has
recovered [4]. The Epstein–Barr virus exerts a transient
suppression of immunoglobulin-coating of bacteria harboured
on the tonsillar surfaces, with consequent abundant bacterial
attachment to the epithelial cells and massive bacterial
colonization on the palatine tonsils and penetration into the
epithelial cells [16,17]. Metronidazole may help to hasten
recovery by suppressing of the oral anaerobic flora that might
contribute to the inflammatory process induced by the
Epstein–Barr virus [2,18].
Our study has again demonstrated that metronidazole has a
role to play in severe infectious mononucleosis. More trials on
a larger scale and possibly in an outpatient setting are required.
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TABLE 1. Results
Metronidazole n = 21 Standard care n = 21 Difference (95%CI) p-Value
Primary endpoints
Length of stay in days, mean (SD) 3.67(1.35) 4.67(1.56) 1 (0.09 to 1.91) 0.032
Secondary endpoints
Persistent high temperature (days) 0.76 1.00 0.238 (0.08 to 1.32) 0.658
Decrease in WCC/day 1.98 2.10 0.12 (0.87 to 1.1) 0.806
Ancillary analysis Steroids n = 12 No steroids n = 30 Difference (95%CI) p-Value
Length of stay in days, mean 4.25 4.13 0.12 (1.2 to 0.95) 0.826
Male n = 19 Female n = 23 Difference (95%CI) p-Value
Length of stay in days, mean 4.21 4.13 0.80 (0.89 to 1.1) 0.868
Greater than 5 days 5 days or less Difference (95%CI) p-Value
Length of stay in days, mean 4.17 4.16 0.16 (0.95 to 9.9) 0.974
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